

# A Review on Neuroinflammation in Alzheimer's Disease

Amitpal

Faculty of Pharmacy, Uttarakhand Technical University, Dehradun, Uttarakhand, India

**Abstract:** *Alzheimer's disease is the most widely recognized age related dynamic neurodegenerative turmoil and the most well-known reason for dementia. It is separated by tricky social and memory unsettling influences, advancing into worldwide psychological hindrance, memory misfortune, conduct and mental aggravations, and subsequent practical impairment. Neurodegeneration is the procedure by which brokenness and loss of the neurons in the Focal sensory system are found in the Advertisement patient. Major pathophysiological marks are affidavit of exceedingly solvent  $A\beta$ , and neurofibrillary tangle for the most part in hippocampus and cerebral cortex are estimated. Irritation unmistakably happens in obsessive profitable area of Promotion mind found harmed neurons, neuritis and dissolvable  $A\beta$ , neurofibrillary tangles gives evident upgrades to irritation in neurodegeneration of AD.*

**Keywords:** Alzheimer's disease, Neuroinflammation, AD model, Medication

## 1. Introduction

Alzheimer's ailment (Advertisement) is a dynamic neurodegenerative strife and the most notable explanation behind dementia, speaking to 60% to 80% of cases. Early signs normally join inconvenience reviewing names and late events, separation, and distress. Later reactions join declining memory, debilitated judgment, bewilderment, disorder, social changes, and inconvenience talking, swallowing, and walking [1]. Neurodegenerative issue is the dynamic loss of structure of neurons, including going of neurons, Promotion is depict by the presences of neuropathological marker's amyloid plaque ( $A\beta$ ) plan intracellular and neurofibrillary tangle (tau) formation intracellular and extracellular in cerebrum. Alzheimer's disease (Promotion) can be parceled into sporadic Advertisement (Tragic) and familial Promotion (Prevailing design). Most Advertisement cases are sporadic and result from various etiologic parts, including normal, genetic, and metabolic components, while Craze is realized by changes in the presenilins (presenilins1, presenilins 2) or amyloid- $\beta$  ( $A\beta$ ) herald protein characteristics. Application is a lone pass transmembrane protein conveyed at anomalous states in the psyche and used in a quick and significantly complex plan by a movement of progressive proteases, including the intramembranous  $\gamma$ -secretase complex, which also process other key managerial molecule. Other essential anomalies are assistant effects of Advertisement, for instance, gliosis, endless disturbance, excitotoxicity, and oxidative weight [2].

### Alzheimer's Disease and its Pathology

Alzheimer's affliction (Advertisement) is the most generally perceived kind of dementia in the old and addresses a critical and extending clinical test similarly as assurance and treatment. Various sub-nuclear wounds have been recognized in Promotion; extracellular amyloid plaques from aggregates of deadly amyloid  $\beta$  ( $A\beta$ ) and intracellular neurofibrillary tangles made out of hyperphosphorylated tau are the portraying bruises in AD,  $A\beta$  is made out of 40 or 42 amino acids and is created through proteolytic cleavage of amyloid harbinger protein [3]. Based on  $A\beta$  course theory various segments and pathways of  $A\beta$  age and articulation have been developed, including free extraordinary age,

oxidative weight, mitochondrial brokenness, provocative methods, inherited components, apoptosis, and aging. presenilin-1 (PS1) or presenilin-2 (PS2). Either PS1 or PS2 can be the reactant subunit of  $\gamma$ -secretase, which is the last endoprotease in the pathway that makes the peptide. Application is progressively isolated by two film bound endoprotease works out,  $\beta$ - and  $\gamma$ -secretase.  $\beta$ -secretase at first cuts off Application to release a considerable produced auxiliary, sAPP $\beta$ . A piece of 99 amino acids (CTF $\beta$ , which begins with the N-terminal aspartyl development of  $A\beta$ ) remains layer bound, and is consequently immediately cut off by  $\gamma$ -secretase to create  $A\beta$ . Cleavage by  $\gamma$ -secretase is somewhat free, realizing a C-terminal heterogeneity of the ensuing peptide,  $\beta$  secretes activity begins from an essential film aspartylpro-trouble encoded by the  $\beta$ -site Application separating enzyme1 gene (BACE1) [4], while  $\gamma$  secretase is a layer bound proteas complex containing something like four fundamental parts: the homologous presenilins1 and 2 (PS1 and 2), nicastrin, Aph-1 and Pen-2 [5]. Tau pathosis are another class of neurodegenerative issue depicted by the microtubule related protein tau (MAPT) into joined helical strands (PHFs) or straight filaments (SFs), molding neurofibrillary tangles (NFTs) at the top of the priority list. [6]. The other two neuronal MAPs are MAP1 and MAP2. A set up limit of MAPs is their correspondence with tubulin and headway of its social gathering into microtubules and change of the microtubule compose. The microtubule get together propelling development of tau, a phosphoprotein, is constrained by its degree of phosphorylation [7].

### Neurodegeneration

Neurons are the essential cells of the CNS and supply it with its particular capacities. Associations between neurons are sanctioned at neurotransmitters, where synapses are discharged in quanta to convey an excitatory or inhibitory sign to the synaptic-target neuron. Cell forms that convey these sign are named axons, while dendrites get synaptic information sources. Every one of the 1011 neurons in the human cerebrum incorporates numerous synaptic contributions from different neurons and for each information got, could conceivably start an axonal activity potential and in this manner give synaptic contribution to its objective neuron a framework containing 1015 associations

in all. Mitochondria are in charge of cell vitality creation. Hindrance of the electron transport chain in mitochondria results in the imbalanced creation of free extreme species, prompting oxidative pressure, and eventually neuronal harm [8]. A-Ketoglutarate dehydrogenase complex, pyruvate dehydrogenase complex, and cytochrome oxidase – rate-restricting chemicals in the mitochondrial respiratory chain and are in charge of decreasing atomic oxygen – have reliably been demonstrated to be engaged with mitochondria brokenness in AD [8,9,10]. Grown-up neurogenesis in mammalian mind continues in a few cerebrum locales, including the hippocampus and the ventricular zone [11,12,13]. Adult neurogenesis incorporates expansion of neural immature microorganisms (NSCs)/Neural ancestor cells (NPCs), relocation of recently framed neurons, separation into a characterized neuronal phenotype, and practical reconciliation to the neural circuits (e.g., neurotransmitter arrangement and transmitter release)[14].

**Neuroinflammation**

Neuroinflammation is an observable component of Alzheimer disease (Promotion) and other ceaseless neurodegenerative messes. It powers the fundamental pathology by creating a lot of ignitable center individuals and neurotoxic blends. Provocative cytokines supplement parts, and risky free radicals are among the various species that are delivered, microglia strikes the over the top substances and may incidentally damage have neurons. Microglia can be animated to expect a relieving state rather than a star red hot state which may have healing potential. Ace provocative cytokines join IL-1, IL-6 and TNF, while

moderating cytokines consolidate IL-4 and IL-10. Supplement sanctioning is an alternate strategy which causes wide neuronal damage in Advertisement through social affair of the layer ambush complex. Neuroinflammation is additionally characterized as a fiery reaction inside the mind or spinal rope. This aggravation is interceded by the generation of cytokines, chemokines, receptive oxygen species, and auxiliary delegates. These go between are created by occupant CNS glia (microglia and astrocytes), endothelial cells, and incidentally inferred resistant cells. There are invulnerable, physiological, biochemical, and mental outcomes of these neuroinflammatory reactions. Besides, the level of neuroinflammation relies upon the unique circumstance, length, and course of the essential boost or affront (Figure 1). For example, aggravation can prompt enlistment of invulnerable cells, edema, tissue harm and possibly cell passing. [15].

Genome Wide Affiliation Studies (GWAS) have recognized more than 20 quality varieties related with an extended risk as of late starting Promotion (Burden), the most unavoidable sort of Advertisement [15]. The disclosures unequivocally entangle characteristics related to the immune response (CR1, CD33, MS4A, CLU, ABCA7, EPHA1 and HLADRB5-HLA-DRB1), endocytosis (BIN1, PICALM, CD2AP, EPHA1 and SORL1) and lipid science (CLU, ABCA7 and SORL1). Aβ is known to incite the commencement of astrocytes and microglia, close by selection of ignitable hailing falls [16-22].

**Table 1:** Identified gene mutations implicated in altered microglial function in AD. (Claudio Villegas-Llerena et., al 2016)<sup>[24]</sup>.

| Gene  | Associated SNP or genetic polymorphism  | Evidence of link to AD   | Predicted ramifications of gene polymorphism to microglial responses  | Protective or risk factor   |
|-------|---|--|---|---|
| TREM2 | rs75932628(R47H) & rs143332484 (R62H)   | TREM mRNA unregulated in AD transgenic mouse brains. Transgenic mice express high levels of TREM2. AD transgenic mice exhibit reduced microglial clustering around plaque.   | Loss of function of receptor Loss of trafficking and maturity of receptor to membrane Loss of phagocytic and migratory properties of microglia and loss of shedding ability of sTREM2 Increase in number of apoptotic cells and plaques Loss of lipid sensing functions   | R47H odds ratio of 2.71 R62H odds ratio of 2.36   |
| CR1   | rs6656401, rs3818361, rs6701713, rs1408077, rs6701710 rs4844610, rs116806486, rs6691117, rs11803956 and LCR1 copy number variation. | rs646817 and rs11803956 linked to elevated cerebrospinal fluid levels of Ab42 in AD patients. rs6656401 influences the severity of vascular amyloid deposition. CR1-S AD cases have higher Braak stages than CR1-F homozygous carriers.  | Fewer binding sites or mutations in binding sites may result in decreased Ab binding and clearance. Alterations to regulation of complement could result in Neuroinflammation   | rs6656401 has strongest association with AD with an odds ratio of 1.21                            |
| CD33  | rs3865444   | Conflicting results: reduced CD33 protein levels associated with this SNP but overall increased CD33 expression in AD brain tissue. Upregulation of CD33 expression results in decreased AB phagocytosis whilst CD33 knockout murine microglia take up more AB42 versus WT cells | Reduced CD33 protein levels predicted to result in loss of function mutation may prevent CD33 inhibiting phagocytosis, resulting in improved microglia clearance of Ab deposits. Increased risk, linking with increased CD33 expression, may reduce Ab uptake and degradation by microglia and monocytes, fueling inflammation. | Odds ratio of 0.94 but in a recent meta-analysis rs3865444 did not reach genome wide significance |
| MS4A  | rs983392 (MS4A6A) rs610932 (MS4A6A) rs670139 (MS4A4E) rs4938933 (intergenic region between MS4A4E & MS4A4A)                         | MS4A4A & MS4A6A expression increased in AD brain. Higher levels of MS4A6A expression in the parietal lobe are associated with more advanced brain pathology in AD patients.  | Function of these genes poorly understood but if similar to others in gene cluster, may code for cell proteins which participate in calcium signalling, to regulating calcium influx and intracellular store calcium or may modify interactions between immune  | rs493838933 has odds ratio of 0.9. rs670139 has odds ratio of 1.08 so is protective               |

|                       |   |   |  |  |
|-----------------------|---|---|--|--|
|                       |   |   | cells such as mast cells and T-cells with microglia in the CNS. Thus dysregulation may alter these functions.  |  |
| CLU                   | rs9331896,rs11136000                      | CLU expression has been shown to be elevated in AD brains and is detected in amyloid. Clusterin directly interacts with Ab and modifies fibril formation in vitro. rs11136000 associated with higher brain levels of clusterin.   | May modify microglial activation via regulation of complement. Alteration of fibril formation may affect Ab clearance.   | rs9331896 has odds ratio of 0.86. rs11136000 is protective odds ratio 0.84   |
| ABCA7                 | rs4147929,rs3764650                       | APP transgenic mice that are ABCA7-deficient show increased Ab deposition compared to controls. ABCA7 expression is increased in AD but the rs3764650 T allele that decreases AD risk is associated with increased ABCA7 expression. rs3764650 is associated with neuritic plaque burden.       | Because of high expression in microglia and role in initiating phagocytosis, a loss of function would result in impaired clearance of apoptotic cells and Ab. ABCA7 SNPs associated with higher AD risk are also linked to higher brain levels of ABCA7. However, the impact of these and other ABCA7 AD-associated SNPs is still poorly understood, thus difficult to predict impact on microglial responses. | Odds ratio of 1.15   |
| HLA-DRB5-<br>HLA-DRB1 | rs9271192                                 | HLA-DR, a component of MHCII, is highly expressed on reactive microglia in AD and PD brain.   | a-synuclein overexpression in mouse brains increases. MHCII in microglia. MHCII knockout in mice protects against a-synuclein induced neurodegeneration. Ab peptides might have a similar effect on MHCII.   | Odds ratio of 1.11   |
| APOE                  | APOE4 allele (homozygous or heterozygous) | Binds Ab peptides and influences the clearance of soluble Ab and the Ab aggregation. The binding efficiency of APOE isoforms to Ab correlates inversely with the risk of developing AD. APOE isoforms are inhibitors of Ab aggregation. Ab peptides induce APOE expression! Feedback mechanism. | Overproduction of APOE, particularly the APOE4, could exacerbate the inflammatory response. The inability of microglia or macrophages to digest the various forms of Ab may lead to enhanced inflammation. The deposition of Ab with fibrinogen may result in a digestion-resistant clot, further fueling inflammatory processes.  | The E4 allele increases AD risk up to 3-fold in heterozygous carriers and up to 15-fold in Homozygous carrier In Icelandic populations, the ApoE e4 allele has an odds ratio of 3.08 |

Amyloid  $\beta$  (A  $\beta$ ) peptide, the real segment of decrepit plaques, amasses in the mind of Alzheimer's malady (AD) [23, 24]. A $\beta$  is delivered by endoproteolysis of the parental amyloid antecedent protein (APP), which is accomplished by the consecutive cleavage of APP by gatherings of chemicals or catalyst buildings named  $\alpha$ -,  $\beta$ - and  $\gamma$ -secretases. Three chemicals with  $\alpha$ -secretase movement have been recognized, all having a place with the ADAM family (a disintegrin-and metalloproteinase-family protein): ADAM9, ADAM10 and ADAM17 (otherwise called tumor putrefaction factor changing over enzyme [25]. The amyloidogenic pathway is an elective cleavage pathway for APP which prompts A $\beta$  age. The underlying proteolysis is interceded by the  $\beta$ -secretase at a position found 99 amino acids from the C end. This cut outcomes in the arrival of sAPP $\beta$  into the extracellular space, and leaves the 99-amino-corrosive C-terminal stub (known as C99) inside the film, with the recently produced N end comparing to the primary amino corrosive of A $\beta$ . Ensuing cleavage of this part (between buildups 38 and 43) by the  $\gamma$ -secretase frees an unblemished A $\beta$  peptide. The vast majority of the full-length A $\beta$  peptide delivered is 40 buildups long (A $\beta$ 40), while a little extent (roughly 10%) is the 42 buildup variation (A $\beta$ 42). The A $\beta$ 42 variation is progressively hydrophobic and more inclined to fibril development than A $\beta$ 40 [26]. There are 32 APP, 179 PSEN1 (presenilin 1 quality locus), and 14 PSEN2 quality transformations that outcome in

early-beginning, autosomal prevailing, completely penetrant AD[27], In APP, changes group around the  $\gamma$ -secretase cleavage site, in spite of the fact that the most well-known APP transformation (APP-sew) causes an adjustment in amino acids neighboring the BACE1 cleavage site. PSEN quality changes (which offer ascent to proteins called presenilins, PS1 and PS2) overwhelmingly adjust the amino acids in their nine trans layer spaces. The consistent idea to every one of these changes is that they increment generation of the not so much solvent but rather more lethal A $\beta$ 42 with respect to A $\beta$ 40 [28].

**Model for Alzheimer's Disease**

A creature model is helpful just on the off chance that it prompts the improvement of a powerful treatment or gives a superior comprehension of the organic systems that underlie the indications of the infection. Creature models of AD have given much data on the capacity of the basal forebrain framework and have been utilized to research the potential viability of different pharmacotherapies intended to switch explicit side effects. The sickness movement, sign and system creature model assumes a significant job to translate and perceive the obscure medication targets. Their capacity is to firmly mirror the malady related obsessive manifestations. These exploratory models can be of in vitro or in vivo beginning. The investigation of Alzheimer's pathology has been fundamentally performed in vivo

exploratory model. In this manner is an extension to build up the in vitro test model for the AD. The in vivo exploratory models of AD are ordered into transgenic and non-transgenic models. Transgenic rat models of AD are fundamentally mice models with couple of changes in quality worried about AD pathology like PS1; APP and so on. PDPP and Tg2576 mice model have application transformation and they have expanded amyloid level and memory shortages. 5xFAD and PSAPP mice model have transformation in APP and PS1 gene, these model have abnormal amyloid generation, neuronal misfortune and subjective debilitation [29].

Non transgenic model includes the organization of poisons in rat cerebrums by various course like Intracerebroventricular course (ICV) and hippocampal course, to actuate the manifestations like AD pathology. Among them basic are AF64A, amyloid beta, okadecarboxylic acid and Streptozotocin [30]. Various type of the amyloid beta (A $\beta$ ) were additionally utilized in intense infusion or interminable imbuement, A $\beta$ 1-40 and A $\beta$ 142 are the most ordinarily utilized either by Intracerebroventricular infusion or intrahippocampal infusion.

#### Available Treatment for AD

Presently no accessible therapeutics could modify the ailment status and couldn't fix the illness. Accessible pharmacological treatments just proposed to give symptomatic relief. Medication at present affirmed by FDA for Alzheimer's incorporate cholinesterase inhibitor (Donepezil, Galantamine, Rivastigmine, Tacrin) and memantine, a N-methyl-D aspartate (NMDA). Cholinesterase inhibitor (ChEI) treatment consists of 2 key stages: A portion acceleration stage to accomplish a clinically successful portion and a support stage, during which the patient is continued at an ideal restorative portion [31]. ChEI class reversible hinder the chemical acetylcholinesterase which breaks the synapse acetylcholine into acetyl CoA and choline consequently keeping up the essential degrees of acetylcholine in brain. The ChEI are ordered by their length of catalyst restraint, short, middle of the road or long acting inhibitors. Tacrine, Donepezil and galantamine specifically hinder the acetylcholinesterase. Galantamine likewise improve cholinergic neurotransmission by activity as an allosteric ligand at nicotinic acetylcholine receptors to increment presynaptic acetylcholine discharge and postsynaptic neurotransmission. Tacrine and Donepezil are short acting operators that dilemma to AChE by hydrogen holding are hydrolyzed inside minutes. Donepezil is an exceedingly explicit, reversible AChEI, Rivastigmine is a moderate reversible inhibitor of both acetylcholinesterase and butyrylcholinesterase and is hydrolyzed by esterase. It isn't processed by cytochrome p450 and its short end half-life requires two portion every day, galantamine is as elective reversible acetylcholinesterase inhibitor and a positive allosteric modulator of nicotinic receptors on pyramidal neurons and is utilized by means of cytochrome p 450 isoenzyme (CYP2D6 and CYP3A4) in the liver. With its terminal end half-existence of around 5 h, two portions are required day by day [32]. Glutamate is excitatory synapse in the cerebrum. Glutamatergic incitement and glutamate over-burden may result in neuronal harm prompting

excitotoxicity. Such excitotoxicity eventually prompts neuronal calcium over-burden and has been ensnared in neurodegenerative disorders. Memantine with moderate affinity, an uncompetitive foe of N-methyl-D-aspartate (NMDA) receptor is the primary medication to received endorsement from FDA for treatment of moderate to extreme AD, memantine is sheltered too endured and work by bloking the channel of NMDARs [33].

## 2. Conclusion

This review is an attempt to provide glimpse of the Neuroinflammation in AD. The systemic fathom completer understand in of AD, Especially assessing the neuroinflammation process cause and direct relationship of specific trigger or contribution factor in AD. Another approach for understanding pathology of AD through modified gene experimental model in vivo and in vitro model for pathology and developing new treatment.

## References

- [1] Raskin J, Cummings J, Hardy J, Schuh K, A Dean R. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. *Current Alzheimer research*. 2015 Oct 1;12(8):712-22.
- [2] Ahmed HH, Salem AM, Sabry GM, Husein AA, Kotob SE. Possible Therapeutic Uses of Salvia triloba and Piper nigrum in Alzheimer's Disease-Induced Rats. *Journal of medicinal food*. 2013 May 1;16(5):437-46.
- [3] Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS  $\beta$ -amyloid in Alzheimer's disease. *Science*. 2010 Dec 24;330(6012):1774-.
- [4] Murphy MP, LeVine III H. Alzheimer's disease and the  $\beta$ -amyloid peptide. *J Alzheimers Dis*. 2010;19(1):311-23.
- [5] Sinha S, Lieberburg I. Cellular mechanisms of  $\beta$ -amyloid production and secretion. *Proceedings of the National Academy of Sciences*. 1999 Sep 28;96(20):11049-53.
- [6] Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y.  $\beta$ -Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *science*. 1999 Oct 22;286(5440):735-41.
- [7] DeBrock S, Destrooper B, Vander Perre S, Hill JA, D'Hooghe TM. Effect of Tumor Necrosis Factor- $\alpha$ , Interleukin-6 and Interleukin-8 on in vitro adhesion of endometrial stromal cells to mesothelial cells. *Fertility and Sterility*. 2003 Sep 1;80:224.
- [8] Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. *Current Alzheimer Research*. 2010 Dec 1;7(8):656-64.
- [9] Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. *Journal of neuroscience research*. 2007 Apr;85(5):919-34.
- [10] Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. *Journal of neural transmission*. 1998 Nov 1;105(8-9):855-70.

- [11] Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM, Nobrega JN. Brain cytochrome oxidase in Alzheimer's disease. *Journal of neurochemistry*. 1992 Aug;59(2):776-9.
- [12] Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. *Annals of neurology*. 1983 Jan 1;13(1):72-8.
- [13] Christian KM, Song H, Ming GL. Functions and dysfunctions of adult hippocampal neurogenesis. *Annual review of neuroscience*. 2014 Jul 8;37:243-62.
- [14] Lepousez G, Valley MT, Lledo PM. The impact of adult neurogenesis on olfactory bulb circuits and computations. *Annual review of physiology*. 2013 Feb 10;75:339-63.
- [15] Yuan TF, Li A, Sun X, Ouyang H, Campos C, Rocha NB, Arias-Carrión O, Machado S, Hou G, So KF. Transgenerational inheritance of paternal neurobehavioral phenotypes: stress, addiction, ageing and metabolism. *Molecular neurobiology*. 2016 Nov 1;53(9):6367-76.
- [16] Pimplikar SW. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. *Journal of clinical immunology*. 2014 Jul 1;34(1):64-9.
- [17] Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological psychiatry*. 2015 Jan 1;77(1):43-51.
- [18] Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *The American Journal of Human Genetics*. 2008 Nov 17;83(5):623-32.
- [19] Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature genetics*. 2009 Oct;41(10):1088.
- [20] Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature genetics*. 2011 May;43(5):429.
- [21] Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. *PloS one*. 2010 Nov 15;5(11):e13950.
- [22] Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nature genetics*. 2011 May;43(5):436.
- [23] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, Jun G, DeStefano AL, Bis JC, Beecham GW, Grenier-Boley B. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature genetics*. 2013 Dec;45(12):1452.
- [24] Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Current opinion in neurobiology*. 2016 Feb 1;36:74-81.
- [25] Allinson TM, Parkin ET, Turner AJ, Hooper NM. ADAMs family members as amyloid precursor protein  $\alpha$ -secretases. *Journal of neuroscience research*. 2003 Nov 1;74(3):342-52.
- [26] Chui, D. H. et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. *Nature Med*. 5, 560-564 (1999).
- [27] <http://www.molgen.ua.ac.be/ADmutations/>
- [28] Shen J, Kelleher RJ. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. *Proceedings of the National Academy of Sciences*. 2007 Jan 9;104(2):403-9.
- [29] Elder GA, Gama Sosa MA, De Gasperi R. Transgenic mouse models of Alzheimer's disease. *Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine: A Journal of Translational and Personalized Medicine*. 2010 Jan;77(1):69-81.
- [30] Kamat PK, Kalani A, Rai S, Swarnkar S, Tota S, Nath C, Tyagi N. Mechanism of oxidative stress and synapse dysfunction in the pathogenesis of Alzheimer's disease: understanding the therapeutic strategies. *Molecular neurobiology*. 2016 Jan 1;53(1):648-61.
- [31] Grossberg GT, Corey-Bloom J, Small GW, Tariot PN. Academic highlights: emerging therapeutic strategies in Alzheimer's disease. *The Journal of clinical psychiatry*. 2004 Feb;65(2):255.
- [32] Reisberg B, Doody R, Stöfler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. *New England Journal of Medicine*. 2003 Apr 3;348(14):1333-41.
- [33] Farlow MR, Graham SM, Alva G. Memantine for the Treatment of Alzheimer's Disease. *Drug safety*. 2008 Jul 1;31(7):577-85.